Aoki KR - Search Results

1

Molecular bases of protective immune responses against botulinum neurotoxin A--how antitoxin antibodies block its action.

Atassi MZ, Dolimbek BZ, Steward LE, Aoki KR. Atassi MZ, et al. Among authors: aoki kr. Crit Rev Immunol. 2007;27(4):319-41. doi: 10.1615/critrevimmunol.v27.i4.30. Crit Rev Immunol. 2007. PMID: 18197812 Review.

2

Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment.

Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR. Atassi MZ, et al. Among authors: aoki kr. Mol Immunol. 2008 Sep;45(15):3878-88. doi: 10.1016/j.molimm.2008.06.031. Epub 2008 Aug 3. Mol Immunol. 2008. PMID: 18676021

3

Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition.

Aoki KR, Smith LA, Atassi MZ. Aoki KR, et al. Crit Rev Immunol. 2010;30(2):167-87. doi: 10.1615/critrevimmunol.v30.i2.50. Crit Rev Immunol. 2010. PMID: 20370628 Review.

4

Inhibition of botulinum neurotoxin a toxic action in vivo by synthetic synaptosome- and blocking antibody-binding regions.

Atassi MZ, Dolimbek BZ, Steward LE, Aoki KR. Atassi MZ, et al. Among authors: aoki kr. Protein J. 2010 Jul;29(5):320-7. doi: 10.1007/s10930-010-9255-3. Protein J. 2010. PMID: 20571899

5

Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin A: antigenic structure of the entire toxin.

Dolimbek BZ, Steward LE, Aoki KR, Atassi MZ. Dolimbek BZ, et al. Among authors: aoki kr. Immunobiology. 2011 Jun;216(6):698-706. doi: 10.1016/j.imbio.2010.10.010. Epub 2010 Nov 4. Immunobiology. 2011. PMID: 21183243

6

Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies.

Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR. Atassi MZ, et al. Among authors: aoki kr. Immunobiology. 2011 Jul;216(7):782-92. doi: 10.1016/j.imbio.2010.12.009. Epub 2010 Dec 25. Immunobiology. 2011. PMID: 21281977

7

Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol-peptide conjugates.

Dolimbek BZ, Aoki KR, Atassi MZ. Dolimbek BZ, et al. Among authors: aoki kr. Immunol Lett. 2011 Jun 30;137(1-2):46-52. doi: 10.1016/j.imlet.2011.02.002. Epub 2011 Feb 13. Immunol Lett. 2011. PMID: 21324340

8

Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.

Atassi MZ, Jankovic J, Steward LE, Aoki KR, Dolimbek BZ. Atassi MZ, et al. Among authors: aoki kr. Immunobiology. 2012 Jan;217(1):17-27. doi: 10.1016/j.imbio.2011.08.009. Epub 2011 Aug 30. Immunobiology. 2012. PMID: 21962573

9

Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains.

Atassi MZ, Oshima M, Dolimbek BZ, Aoki KR. Atassi MZ, et al. Among authors: aoki kr. Immunobiology. 2012 Jan;217(1):1-7. doi: 10.1016/j.imbio.2011.09.001. Epub 2011 Sep 16. Immunobiology. 2012. PMID: 22015045

10

Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.

Oshima M, Deitiker PR, Jankovic J, Duane DD, Aoki KR, Atassi MZ. Oshima M, et al. Among authors: aoki kr. J Neuroimmunol. 2011 Dec 15;240-241:121-8. doi: 10.1016/j.jneuroim.2011.10.005. Epub 2011 Nov 12. J Neuroimmunol. 2011. PMID: 22079193

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

74 results

Search Page